دورية أكاديمية

Stem‐cell therapy in ST‐segment elevation myocardial infarction with reduced ejection fraction: A multicenter, double‐blind randomized trial

التفاصيل البيبلوغرافية
العنوان: Stem‐cell therapy in ST‐segment elevation myocardial infarction with reduced ejection fraction: A multicenter, double‐blind randomized trial
المؤلفون: Nicolau, José C., Furtado, Remo H.M., Silva, Suzana A., Rochitte, Carlos E., Rassi, Anis, Moraes, João B.M.C., Quintella, Edgard, Costantini, Costantino R., Korman, Adrian P.M., Mattos, Marco A., Castello, Hélio J., Caixeta, Adriano, Dohmann, Hans F.R., de Carvalho, Antonio C.C.
المساهمون: Ministry of Health-Brazil, Finance Agency for Studies and Projects (FINEP)
المصدر: Clinical Cardiology ; volume 41, issue 3, page 392-399 ; ISSN 0160-9289 1932-8737
بيانات النشر: Wiley
سنة النشر: 2018
المجموعة: Wiley Online Library (Open Access Articles via Crossref)
الوصف: Background Left ventricular ejection fraction (LVEF) is a major determinant of long‐term prognosis after ST‐segment elevation myocardial infarction (STEMI). STEMI patients with reduced LVEF have a poor prognosis, despite successful reperfusion and the use of renin‐angiotensin‐aldosterone inhibitors. Hypothesis Intracoronary infusion of bone marrow–derived mononuclear cells (BMMC) may improve LVEF in STEMI patients successfully reperfused. Methods The main inclusion criteria for this double‐blind, randomized, multicenter study were patient age 30 to 80 years, LVEF ≤50%, successful angioplasty of infarct‐related artery, and regional dysfunction in the infarct‐related area analyzed before cell injection. Cardiac magnetic resonance imaging was used to assess LVEF, left ventricular volumes, and infarct size at 7 to 9 days and 6 months post–myocardial infarction. Results One hundred and twenty‐one patients were included (66 patients in the BMMC group and 55 patients in the placebo group). The primary endpoint, mean LVEF, was similar between both groups at baseline (44.63% ± 10.74% vs 42.23% ± 10.33%; P = 0.21) and at 6 months (44.74% ± 12.95 % vs 43.50 ± 12.43%; P = 0.59). The groups were also similar regarding the difference between baseline and 6 months (0.11% ± 8.5% vs 1.27% ± 8.93%; P = 0.46). Other parameters of left ventricular remodeling, such as systolic and diastolic volumes, as well as infarct size, were also similar between groups. Conclusions In this randomized, multicenter, double‐blind trial, BMMC intracoronary infusion did not improve left ventricular remodeling or decrease infarct size.
نوع الوثيقة: article in journal/newspaper
اللغة: English
DOI: 10.1002/clc.22882
الإتاحة: https://doi.org/10.1002/clc.22882Test
حقوق: http://onlinelibrary.wiley.com/termsAndConditions#vorTest
رقم الانضمام: edsbas.72E615B1
قاعدة البيانات: BASE